Soluble fibers from psyllium improve glycemic response and body weight among diabetes type 2 patients (randomized control trial) by Ayman S. Abutair et al.
RESEARCH Open Access
Soluble fibers from psyllium improve
glycemic response and body weight
among diabetes type 2 patients
(randomized control trial)
Ayman S. Abutair*, Ihab A. Naser and Amin T. Hamed
Abstract
Background: Water-soluble dietary fibers intake may help control blood glucose and body weight.
Objective: The objective of the study was to determine whether soluble fiber supplementation from psyllium
improves glycemic control indicators and body weight in type 2 diabetic patients.
Method: Forty type 2 diabetes patients, non-smoker, aged >35 years were stratified to different strata according to
sex, age, body mass index (BMI) and fasting blood sugar level (FBS) and randomly assigned into two groups; The
intervention group which consists of 20 participants was on soluble fiber (10.5 g daily), and the control group
which consist of 20 participants continued on their regular diet for eight weeks duration.
Results: After 8 weeks of intervention, soluble fiber supplementation showed significant reduction in the
intervention group in BMI (p < 0.001) when compared with the control group. Moreover, water soluble fiber
supplementation proven to improve FBS (163 to 119 mg/dl), HbA1c (8.5 to 7.5 %), insulin level (27.9 to 19.7 μIU/mL),
C-peptide (5.8 to 3.8 ng/ml), HOMA.IR (11.3 to 5.8) and HOMA-β % (103 to 141 %).
Conclusion: The reduction in glycemic response was enhanced by combining soluble fiber to the normal diet.
Consumption of foods containing moderate amounts of these fibers may improve glucose metabolism and lipid
profile in type 2 diabetes patients.
Trial registration: Current Controlled Trials PHRC/HC/28/15 .
Keywords: Diabetes, Fiber, Fasting blood sugar, Insulin, Body weight
Background
Diabetes is the fastest growing chronic condition world-
wide. According to Centers for Disease Control and
Prevention (CDC), 9.3 % of the U.S. population have dia-
betes [1]. By 2035 the number of adults having diabetes
will increase from 387 to 592 million worldwide [2]. It’s
now well established that diabetes increases the chances
for serious complication such as heart diseases and asso-
ciated mortality [3]. Diet, exercise and behavioral
approaches represent the key for management and pre-
vention of diabetes [4, 5]. More important, consumption
of dietary fibers were inversely related to type 2 diabetes
and cardiovascular disease [6]. Researchers stressed that,
consumption of more than 26 g a day had an 18 % lower
risk of developing type 2 diabetes than those with the
lowest intake [7]. Fiber is commonly classified as soluble,
which dissolves in water or insoluble, which doesn’t dis-
solve [8]. The soluble fibers can dissolves in water to
form a gel-like material. Soluble fiber is found in oats,
peas, beans, apples, citrus fruits, carrots, barley and psyl-
lium [8]. Interestingly, the solubility of soluble fiber re-
fers to its ability to dissolve in water, forming viscous
gels, bypasses the digestion of the small intestine [9],
and slows absorption and digestion of carbohydrates
[10]. Psyllium is a water-soluble fiber derived from the
husks of ripe seeds from Plantago ovate [11], that may
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improves glycemic control [12–14], body weight [15]
and improve bowel movement [16] in patients with type
2 diabetes. On the other hand, increased consumption of
high glycemic index food was associated with insulin re-
sistance and increased prevalence of metabolic syndrome
in patients with type 2 diabetes [17]. The purpose of this
study was to investigate the beneficial effects of adding
soluble fiber to the normal diet for eight weeks of inter-
vention among diabetes type 2 patients.
Methods and material
Study design and setting
This study utilized randomized controlled trial design,
with newly identified Type 2 diabetes patients (max-
imum one year) who were on anti-diabetes medication.
Aged more than 35 years of old, male and female and
who attend private endocrine clinics in the Gaza Strip.
Sample size was calculated using two mean formula,
which indicated that 18 respondents in each subjects.
However, to ensure power to reach desired statistical
outcomes and allow for voluntarily withdrawal, number
of subjects were increased to 20 in per group. The study
included 20 male and 20 female patients. To insure
equal distribution of cases, the subjects were stratified
according to sex (male/female), age (35–45 years/45–
50 years/50–55 years/55–60 years), BMI (25–29.99/30–
34.99/35–39.99) and fasting glucose level (110–149 mg,
150–200 mg) into homogeneous strata, then the subjects
were allocated randomly in to intervention and control
group. The control group consists of 20 participants did
not receive any food supplements throughout the inter-
vention period and instead continued with their regular
diets. While, the intervention group consists of 20 par-
ticipants, and received soluble fiber 10.5 g daily for eight
weeks of intervention.
Intervention protocol
Soluble fiber was provided to the intervention group in
this study, whereas the control group remained on their
regular diet. Both groups were on their regular diet and
lifestyle. The intervention protocol was designed in a
way that 7.0 g of psyllium was given to the intervention
group 15 min before lunch and 3.5 g of psyllium 15 min
before dinner with 150 ml of water with each dose. To
avoid choking while consuming the psyllium supple-
ments. Respondents instructed to consume psyllium
with an adequate amount of water (first melt the fiber
dose well in 100 ml of water and drink it, then drink
additional 50 ml of water). To insure subjects compli-
ance to the intervention program, subjects were con-
tacted by phone 3 times weekly and they were instructed
to fill up the compliance checklists to record the daily
consumption of the soluble fiber doses, these checklists
were collected weekly.
Dietary stabilization phase
During a dietary stabilization phase, subjects in both
groups were instructed to follow a prescribed diet plan
for one week for diabetes, to stabilize the serum glucose
level (≤30 % of total energy as fat,≤10 % of energy as sat-
urated fat, and ≥55 % of energy as carbohydrate- focused
on complex carbohydrate). Dietary stabilization was not
the major focus of this intervention and the main goal of
dietary instruction was to encourage subjects to main-
tain their same dietary patterns throughout the
stabilization phase. Also, we have prepared a diet pro-
gram for diabetes patients for one week, and calories
was calculated based on body weight for each participant
(25 Kcal multiplied by body weight Kg).
Measurements
Anthropometric measurements and biochemical indica-
tors were taken at the baseline, and at the end of the
trial. Weight was taken in kilograms and grams. Also, re-
spondents were weighted pre and post intervention with
same minimal clothing, without shoes or other heavy ac-
cessories such as mobile phones and wallets. Heights
measurements were taken using calibrated Stadiometer.
Respondents stand with bare feet that are kept together
and the head was level with a horizontal Frankfurt plane
below an imaginary line from the lower border of the
eye orbit to the auditory meatus [18]. Heights were mea-
sured in centimeters and millimeters. In addition, the
commonly accepted BMI ranges are underweight: under
18.5, normal weight: from 18.5 to 24.9, overweight: from
25 to 29.9, obese: over 30. Furthermore, waist circumfer-
ence was measured at the midpoint between the lower
margin of the last palpable rib and the top of the iliac
crest, using a stretch resistant tape [19]. According to
the WHO, waist circumference more than 102 cm for
adult male and more than 88 cm for adult non-pregnant
female indicate risk for obesity and its health complica-
tions risks [19]. Also, hip circumference is measured in a
similar manner to waist circumferences, with the tape
being passed around the hips at the widest circumfer-
ence of the buttocks and the tape measure be kept level
and parallel to the floor whilst the measurement is
made. The average of three measurements was recorded.
Waist to hip ratio (WHR) is the ratio of the circumfer-
ence of the waist to that of the hips. This is calculated as
waist measurement divided by hip measurement (W/H).
WHR is used as a measurement of obesity, which in turn
is a possible indicator of other more serious health con-
ditions. The WHO states that abdominal obesity is de-
fined as a WHR above 0.90 for males and above 0.85 for
females [19]. The Measured biochemical parameters
include insulin level, FBS, hemoglobin A1c, C-peptide.
HOMA-IR and HOMA-B% were calculated in order to
predict insulin sensitivity and Beta cell function according
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to the following formulas: HOMA-IR = (glucose mg * in-
sulin level)/405, and HOMA-B% = (360* insulin level)/
(glucose mg – 63) [20].
Kits and devices
The device used for F.B.S. analysis was (Mindry semi-
auto chemistry, model BA-88A, S.N WR-04002031) and
the kit that was used in this device was (Bio Med-
Glucose L.S, normal level in the plasma 60–110 mg/dl,
and sensitivity: 0.4 mg/dl). The device used for HbA1c
analysis was (ClOVER A1c analyzer, model IGM-0023,
S.N GWLHCLD0056) and the kit used was (CLOVER
A1c test cartridge and used with ClOVER A1c analyzer
only, less than 7 % is the treatment goal). The device
used for insulin and C-peptide analysis was (Mindry
micoplate reader, model MR-691A, S.N. 4100566) and
the kits used for Insulin was (DRG Insulin ELISA EIA-
2935, normal value 2–25 μIU/mL, sensitivity: 1.76 μIU/
mL) and for C-Peptide was (DRG C-Peptide ELISA EIA-
1293, normal value: 0.5-3.2 ng/ml, sensitivity: 0.064 ng/ml).
Data analysis
Following data collection, all data was reviewed before
being entered into the study database. Data were entered
into an SPSS (Statistical Package for Social Sciences) ver-
sion 18.0 for Windows. The data treatment involved
cleaning and organizing the data for analysis, which in-
cluded numbering the results, codifying the data, enter-
ing the data into the computer, checking the data for
accuracy. The data analysis was divided into two steps:
descriptive statistics and analysis of variance. The data
are presented in tables. The quantitative data are repre-
sented in the form of proportions (%) and of means with
standard deviations or medians. All measurements and
indicators of the two groups were compared at the base-
line, and after eight weeks of intervention to evaluate
the impact of the intervention. To compare the changes
in the glycemic control indicators and anthropometric
measurements one-way repeated measure ANOVA was
used. The level of significance was set at 0.05.
Results
Out of 40 subjects four respondents withdrew during
the study period, and 36 respondents have completed
the trial from the beginning to the end of the study suc-
cessfully. None of the remaining participants were re-
moved from the entire database, and no missing data
was observed of all important variables.
Anthropometric characteristics for both groups at
baseline level
Table 1 presents the anthropometric characteristics of
the respondents for both groups. The mean weight for
respondents was 89 kg SD (13.91), the mean height was
1.7 m SD (0.11) and the mean BMI was 31.7 (kg/m2) SD
(2.71), the majority of the respondents 25 (69.4 %) were
obese and ranged from class I to class II. The mean
waist circumferences was 106.8 (7.30) cm, and the re-
sults showed that the majority of male respondents 17
(94.4 %) waist circumference were more than normal cut
of points 102 cm for adult male. All female respondents
waist circumference were more than normal cut of
points 88 cm for adult female. The mean hip circumfer-
ences for respondents was 108.8 (7.79) cm. The WHR
mean of all respondents was 0.99 (0.09).
Changes in the anthropometric measurements
After 8 weeks of intervention, significant changes were
observed in the majority of anthropometric measure-
ments in either group (Table 2). In intervention group,
the weight, BMI, waist circumference and hip circumfer-
ence were significantly decreased (weight (2.7 kg, p <
0.001), BMI (0.98 kg/m2, p < 0.001), waist circumference
(2.6 cm, p < 0.001), and hip-circumference (2.5 cm, p <
0.001)). The WHR shows some reduction about 0.0019,
in which this reduction was not significant. Psyllium
supplementation showed significant improvement on an-
thropometrics as compared with the control group by
Table 1 Anthropometric characteristics of all respondents
Variables Total







Waist circumferences 106.8 (7.30)
More than 102 cm (male) 17 (94.4)
Less than 102 cm (male) 1 (5.6)
More than 88 cm (female) 18 (100)
Less than 88 cm (female) 0 (0.00)
Hip circumferences 108.8 (7.79)
Waist to Hip Ratio a 0.99 (0.09)
0.95 or less low risk (male) 4 (22.2)
0.96–1.0 moderate risk (male) 2 (11.1)
More than 1.0 high risk (male) 12 (66.7)
0.80 or less low risk (female) 0 (0.00)
0.81–0.85 Moderate risk (female) 2 (11.1)
More than 0.85 high risk (female) 16 (88.9)
a Health Risk Based Solely on waist to hip ratio (WHR) for male (low risk 0.95
or below, moderate risk 0.96–1 and high risk more than 1, and for female (low
risk 0.95 or below, moderate risk 0.96–1 and high risk more than 1
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repeated test for treatment (time x treatment
interaction).
Glycemic control indicators characteristics for both
groups at baseline level
Table 3 presents the glycemic control characteristics of
the respondents for both groups. The mean FBS was
160 mg/dl, and all the respondents were above normal
cut off point which is 110 mg/dl. The mean of HbA1c
was 8.5 (0.654) and the majority of respondents 26
(72.2 %) were above normal cut off point which is from
6 to 8 %, and the mean insulin level was 24.8 μIU/mL,
and 50 % of respondents were in normal reference range
(2–25 μIU/mL), and 50 % were higher than the normal
reference range, In addition, the mean C-peptide level
was 5.5 ng/ml, and the majority of respondents 35
(97.2 %) were above the normal reference range which is
0.5–3.2 ng/ml. Moreover, the mean HOMA-IR and
HOMA-B% were 9.9 and 94.2 respectively.
Changes in the glycemic control indicators
Changes of glycemic control indicators after 8 weeks of
intervention are shown in Table 4. In which FBS,
HbA1c, insulin level, C-peptide and HOMA.IR.
HOMA.B% were improved significantly in intervention
group (43.6 mg/dl p < 0.001, 0,9 % p = 0.013, 8.3 μIU/mL
p < 0.001, 2 ng/ml p < 0.001, 5.5 p < 0.001, respectively)
after 8 weeks of intervention. As a result, the supple-
mentation of soluble fiber improved the majority of gly-
cemic control indicators significantly in the intervention
group as compared with the control group by repeated
test for treatment (time x treatment interaction).
Discussion
Anthropometric changes
At base line level, the mean BMI was 31.7 (2.71) (kg/
m2), while the majority of the respondents 25 (69.4 %)
were obese and ranged from class I to class II. The ma-
jority of male respondents 17 (94.4 %) waist circumfer-
ences were more than normal cut of points [21], and all
of the female respondents 18 (100 %) waist circumfer-
ences were more than normal cut of points [21]. This
study indicated that, the inclusion of 10.5 g of psyllium
with daily diet decreased (weight (from 91.7 to 88.8 kg,
p < 0.001), BMI (from 31.8 to 30.9 kg/m2, p < 0.001),
waist circumference (from 106.2 to 107.3 cm, p < 0.001),
hip circumference (from 109.9 to 107.3 cm, p < 0.001).
Unfortunately, results showed significant increment in
weight, BMI and waist circumference of the respondents
in the control group. Our results are consistent with
those of pal et al. study in which the body weight and
other anthropometric measurements were significantly
improved [22]. This changes in anthropometric mea-
surements might be achieved by stimulation of satiety
hormones production that’s enhancing satiety [23], An-
other study confirmed that, increase in fiber intake with
regular diet has resulted desirable outcomes such as; in-
creased satiety, reduced hunger, decreased energy intake,
Table 2 Differences in anthropometrics in the control and intervention groups
Variables Control (n = 18) Intervention (n = 18) P value a
Pre Post Pre Post
Weight (kg) 87.3 (13.45)b 88.1 (13.379)** 91.7 (14.42) 88.8 (14.78)*** <0.001
BMI (kg/m2) 31.5 (2.66) 31.8 (2.66)** 31.8 (2.82) 30.9 (2.94)*** <0.001
W.C. (cm) 107.5 (7.07) 107.9 (6.77) 106.2 (7.66) 103.5 (7.65)*** <0.001
Hip.C. (cm) 107.8 (7.84) 108.3 (7.87)* 109.9 (7.82) 107.3 (7.96)*** <0.001
WHR 1.00 (0.100) 1.00 (0.100) 0.97 (0.073) 0.97 (0.072) 0.912
a Repeated Measure ANOVA between Control and intervention groups
b Mean (Standard Deviation)
The level of significance is < 0.05
Asterisk = significantly different by paired t-test between baseline and 8th week in the same intervention group, *p < 0.05, **p < 0.01, *** p < 0.001
Table 3 Glycemic control indicators characteristics of all
respondents
Variables Total
n (%) Mean (SD)
Fasting blood sugar 160 (18.33)
Normal range 1 (1.7)
110-149 mg/dl 14 (38.9)
150–200 mg/dl 22 (61.1)
HbA1c 8.5 (0.654)
Within normal level % 10 (27.8)
More than 8 % 26 (72.2)
Insulin level 24.8 (5.916)
Within normal range 18 (50.00)
More than 25 18 (50.00)
C-peptide 5.5 (1.51)
Within normal range 1 (2.8)
More than 5 35 (97.2)
HOMA-IR 9.9 (2.824)
HOMA-B% 94.2 (24.375)
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increase on chewing time and weight loss [24]. More-
over, fiber itself less energy dense if a large volume is
consumed. Fiber-rich food is processed more slowly
than other food types [25]. Increased consumption of
soluble dietary fiber lead to increase the viscosity in
the gastrointestinal tract, improving post meal satiety
and decreased subsequent hunger [26–28]. More im-
portantly, satiety can be reached by different proposed
mechanisms which include; gastric distension [26],
slower absorption of macronutrients resulting in a re-
duction in postprandial glycemia [29], and enhanced
effects of hunger-related hormones such as chole-
cystokinin, glucagon-like peptide-1 and peptide YY
[30]. However, not all studies indicated significant
effects of dietry fibers in satiety and body weight
regulation [24, 27, 31, 32].
Glycemic control indicators changes
The magnitude of glycemic control indicators reduction
seen in this study were seen in other clinical trials.
Feinglos et al., in his clinical trial noted that 3.4 g dose
and 6.8 g dose of psyllium significantly lowered HbA1c
and FBS [33]. Another study concluded that, a psyllium
dose of 5.1 g/day significantly reduced FBS and HbA1c
[34]. Likewise, in the current study all glycemic control
indicators were significantly improved when these
changes compared FBS, HbA1c, insulin and C-peptide
p < 0.001, p < 0.001, p < 0.001, p = 0.001, respectively).
Interestingly, these positive results were achieved due
to soluble fiber effect in reducing glucose absorption
about 12.2 % and as therapeutic agent for other meta-
bolic control [35], while regular intake of soluble fi-
bers, particularly may have a protective role for the
presence of metabolic syndrome of patients with type
2 DM [13]. Though, psyllium as an example of vis-
cose functional water soluble fiber which may delay
intestinal transit time and leading to feel fullness [36],
retarding the entry of glucose into the bloodstream
and lessening the postprandial rise in blood sugar
[37]. It may lessen insulin requirements [38]. Soluble
fiber may produce a slower and longer-lasting release
and absorption of macronutrients due to increased
intraluminal viscosity [26, 39]. In the intestine, the
gel-like material that formed by soluble fiber traps
nutrients inside its gel and slows down considerably
while passing through the digestive tract. Inside the
gel, nutrients are protected from the action of digest-
ive enzymes and less likely to reach the wall of the
intestines for absorption [40]. This lowers the sharp
rise of blood sugar after meal, and improves the sen-
sitivity of the cells to the action of insulin [40]. In
addition, Water soluble fiber thickens the unstirred
water layer covering the surface of the intestines,
which make the nutrients more resistant to cross this
layer and to diffuse into the body [41]. Also, it has
been reported that, soluble fiber decreased postpran-
dial glucose and insulin responses and influenced
concomitant gastrointestinal (GI) peptide responses,
especially ghrelin and Peptide YY release [39]. An-
other clinical trial showed that psyllium improve FBS,
insulin, HOMA Index, HbA1c significantly [42]. An-
other randomized crossover study, demonstrated that
high intake of dietary fiber, particularly of the soluble
type, improves glycemic control, decreases hyperinsu-
linemia and lowers plasma lipid concentrations in pa-
tients with type 2 diabetes [43]. In addition, the use
of HOMA for assessment of β-cell function and insu-
lin sensitivity which can detect the pathophysiology in
those with abnormal glucose tolerance, thus HOMA
is useful analysis tool of the treatment [44]. Conse-
quently, recent studies among hyperglycemic individ-
uals with no prior diagnosis of diabetes mellitus
found to improve insulin sensitivity and other import-
ant metabolic controls [45–49]. This is most likely
due to the viscosity of soluble fibers inside the gastro-
intestinal tract [29].
Table 4 Differences in glycemic control indicators in the control and intervention groups
Variables Control (n = 18) Intervention (n = 18) P value a
Pre Post Pre Post
FBS (mg/dl) 156 (18.28)b 151 (11.65) 163 (18.26) 120 (16.48)*** <0.001
HbA1c (%) 8.5 (0.62) 8.5 (0.56) 8.5 (0.69) 7.5 (0.54)*** <0.001
Insulin (μIU/mL) 21.8 (5.39) 24.9 (5.13)* 27.9 (4.81) 19.7 (2.90)*** <0.001
C-peptide (ng/ml) 5.2 (1.63) 6.3 (1.26)*** 5.8 (1.35) 3.8 (0.91)*** <0.001
HOMA.IR 8.5 (2.62) 9.3 (2.15) 11.3 (2.34) 5.8 (1.12)*** <0.001
HOMA.B% 85.5 (21.40) 102.5 (21.77)* 102.9 (24.59) 140.7 (60.89)** 0.239
a Repeated Measure ANOVA between Control and intervention groups
b Mean (Standard Deviation)
The level of significance is < 0.05
Asterisk = significantly different by paired t-test between baseline and 8th week in the same intervention group, *p < 0.05, **p < 0.01, *** p < 0.001
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Conclusion
It seems that soluble fiber from psyllium deserves atten-
tion as a potential natural dietary supplements for use in
nutritional rehabilitation of type 2 diabetic patients, as it
is inexpensive and shows positive results within a short
span of time.
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